ERBB2 and breast cancer: Díaz-Beltrán et al. [125] used an untargeted LC-HRMS metabolomics strategy to distinguish BC subtypes, and identified biomarker panels containing five candidates for LA, seven for LB, five for HER2+, and three for TN.